Clinical Efficacy of Tislelizumab Combined with First-line Chemotherapy in the Treatment of Advanced Esophageal Cancer Patients and Its Impact on Serum Tumor Markers
Objective:To investigate the clinical efficacy of Tislelizumab combined with first-line chemotherapy in the treatment of advanced esophageal cancer patients and its impact on serum tumor markers.Method:A retrospective analysis was conducted on 86 patients with advanced esophageal cancer who visited the Oncology Department of Zhenjiang First People's Hospital from August 2020 to March 2023 as the study subjects.A total of 43 patients who did not use Tislelizumab before January 2022 were enrolled as the control group,and 43 patients who used Tislelizumab in January 2022 were enrolled as the study group.The control group patients were treated with Paclitaxel Liposome and Nedaplatin,while the study group patients were treated with Tislelizumab in combination on the basis of the control group.The differences in serum tumor markers[squamous cell carcinoma antigen(SCCA),phosphorylated protein kinase B(p-Akt),phosphatidylinositol 3-kinase(PI3K)],immune function indicators[systemic inflammatory index(SII),neutrophils/lymphocytes rate(NLR),platelets/lymphocytes rate(PLR)],and quality of life[quality of life instrument for patients with esophageal cancer(QLICP-ES)]between two groups of patients before and after 4 cycles of treatment were compared,the efficacy and toxicity of two groups of patients after 4 cycles of treatment were compared.Result:After 4 cycles of treatment,the levels of SCCA,p-Akt,SII,NLR PLR and scores of QLICP-ES in both groups decreased,and those in the study group were lower than those in the control group,with statistically significant differences(P<0.05).After 4 cycles of treatment,the efficacy of the study group patients was better than that of the control group,with a statistically significant difference(P<0.05).However,there was no statistically significant difference in the incidence of toxic side effects(P>0.05).Conclusion:The combination of Tislelizumab and first-line chemotherapy in the treatment of advanced esophageal cancer patients can effectively reduce the levels of tumor markers in the patient's serum,enhance immune function,enhance efficacy,and has certain safety.
TislelizumabFirst line chemotherapyEsophageal cancerSerum tumor markers
万方数据
维普
